Mar 2, 2020
MediSieve Receives the Patent in the US For the Magnetic Mixing Device
MediSieve has finally received the second patent (Patent number US10639602B2) for the Magnetic Mixing device in the US
LONDON – March 02, 2020 – MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, has finally received the second patent (Patent number US10639602B2) from the US patent office for the Magnetic Mixing device in the US in March 2020, after filing an application in 2017. The first patent was received in 2019. Although jurisdictions around the world are still pending the second grant solidified MediSieve's Intellectual Property position in the US.
The technology can potentially transform the treatment of blood-borne diseases including acute hyperinflammation, oncology and malaria in a process that’s similar to dialysis. The Magnetic Mixing device increases the binding efficiency between MediSieve's magnetic particles and their targets in a patient’s bloodstream. The Magnet works by concentrating magnetic nanoparticles and microbeads, making it ready to be separated and purified. The particles and their bound harmful compounds can then be extracted, removing the harmful substances from the patient's blood.
The haemofiltration of Il-6 is currently at the pre-clinical stage and offers the benefits of IL-6 inhibitors without the downsides, such as immunosuppression. Furthermore, the Magnet is reusable and compatible with standard hospital equipment, making it cost efficient and fairly easy to use.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
